Teva Releases Q2 2025 Aide Memoire
Teva Pharmaceutical Industries (NYSE:TEVA) has released its Q2 2025 Aide Memoire document, which is now accessible on the company's investor relations website. The document serves as a financial modeling aid for analysts and investors, incorporating historical performance data, management's business outlook, and selected third-party information.
Teva Pharmaceutical Industries (NYSE:TEVA) ha pubblicato il documento Aide Memoire relativo al secondo trimestre del 2025, ora disponibile sul sito web delle relazioni con gli investitori della società. Il documento funge da supporto per la modellizzazione finanziaria di analisti e investitori, includendo dati storici sulle performance, le prospettive aziendali della direzione e informazioni selezionate di terze parti.
Teva Pharmaceutical Industries (NYSE:TEVA) ha publicado su documento Aide Memoire del segundo trimestre de 2025, que ya está disponible en el sitio web de relaciones con inversores de la compañía. El documento sirve como ayuda para la modelización financiera para analistas e inversores, incorporando datos históricos de rendimiento, la perspectiva empresarial de la dirección y información seleccionada de terceros.
Teva Pharmaceutical Industries (NYSE:TEVA)는 2025년 2분기 Aide Memoire 문서를 발표했으며, 현재 회사 투자자 관계 웹사이트에서 확인할 수 있습니다. 이 문서는 과거 실적 데이터, 경영진의 사업 전망 및 선정된 제3자 정보를 포함하여 분석가와 투자자를 위한 재무 모델링 지원 자료로 활용됩니다.
Teva Pharmaceutical Industries (NYSE:TEVA) a publié son document Aide Mémoire pour le deuxième trimestre 2025, désormais accessible sur le site web des relations investisseurs de la société. Ce document sert d’outil de modélisation financière pour les analystes et investisseurs, intégrant les données de performance historiques, les perspectives commerciales de la direction et des informations sélectionnées de tiers.
Teva Pharmaceutical Industries (NYSE:TEVA) hat sein Aide Memoire für das zweite Quartal 2025 veröffentlicht, das nun auf der Investor-Relations-Website des Unternehmens verfügbar ist. Das Dokument dient als Hilfsmittel für die Finanzmodellierung von Analysten und Investoren und enthält historische Leistungsdaten, die Geschäftsaussichten des Managements sowie ausgewählte Informationen Dritter.
- None.
- None.
TEL AVIV, Israel, June 26, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that its Q2 2025 Aide Memoire is available on the “Investors” page on its website.
Teva has prepared this document to assist in the financial modeling of its quarterly results. The document is based on Teva’s prior results, management’s previous commentary about Teva’s business outlook and data from select independent sources.
About Teva
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a different kind of global biopharmaceutical leader, one that operates across the full spectrum of innovation to reliably deliver medicines to patients worldwide. For over 120 years, Teva’s commitment to bettering health has never wavered. Today, the company’s global network of capabilities enables its 37,000 employees across 57 markets to advance health by developing medicines for the future while championing the production of generics and biologics. We are dedicated to addressing patients’ needs, now and in the future. Moving forward together with science that treats, inspired by the people we serve. To learn more about how Teva is all in for better health, visit www.tevapharm.com.
Cautionary Note Regarding Forward-Looking Statements
This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to: our ability to successfully compete in the marketplace; our significant indebtedness; our business and operations in general; compliance, regulatory and litigation matters; other financial and economic risks; and other factors discussed in this press release, in our Quarterly Report on Form 10-Q for the first quarter of 2025, and in our Annual Report on Form 10-K for the year ended December 31, 2024, including in the sections captioned "Risk Factors.” Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.
Teva Media Inquiries
TevaCommunicationsNorthAmerica@tevapharm.com
Teva Investor Relations Inquires
TevaIR@Tevapharm.com
FAQ
What is the Q2 2025 Aide Memoire released by Teva (TEVA)?
Where can investors find Teva's Q2 2025 Aide Memoire document?
What information does Teva's Q2 2025 Aide Memoire include?
When did Teva release its Q2 2025 Aide Memoire?
